MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/omcr/omz134

Медицинская библиотека · Oxford medical case reports · 2020

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris.

Palazzo Giovanni

Клинический случайСтатьяПеревод в очереди

Аннотация

Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-α (TNF-α) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-α inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1 year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.

Для цитирования: Palazzo Giovanni. Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris.. Oxford medical case reports. 2020. DOI: 10.1093/omcr/omz134.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.